CTRI/2012/03/002531Other2 期
â??Double-blind, randomized study to evaluate the ability of H-009 and Arsenic-sulphuricum-flavum in stimulating pigmentation in vitiligo and examining safety in patientsâ?? - nil
Homeopathy India Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with focal vitiligo. Focal vitiligo This type is characterized by one or more lesions in single area.
- •Patient is willing and able to give written informed consent
- •Vitiligo stable since 3 months, that is, there should have been no increase of spots in number or size, during last three months.
- •Patient having vitiligo spots, size up less than 15cm x 15cm.
排除标准
- •Patient having extensive vitiligo, bilateral symmetrical or having onlymuco-cutaneus junction (such as lips, genitals, finger-tips, etc.) affection.
- •Any form of systemic, injectable or topical treatment (conventional, homeopathic, Ayurvedic, Cuben, Phototheraphy, surgical, laser, etc.) during the last 2 months
- •Patients having uncontrolled or untreated under active Thyroid. (To be ruled out by TSH study.)
- •Patient who are on or have consumed in last three months any anti-cancer (conventional) medication.
- •Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable contraceptive method, or do not agree to practice reliable contraception during the study.
- •Current Participation or participation in last 3 months period, in any clinical trial.
- •Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality, disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator may endanger the subject or interfere with the endpoints of study.
研究者
相似试验
尚未招募
3 期
Management of chronic stable angina with an integrated approach of allopathic and ayurvedic medicationsCTRI/2023/06/054147Shathyu Ayurveda Pvt Ltd
已完成
3 期
A randomized, double-blind study to evaluate the safety and effectiveness of the Exhale Drug-eluting stent in homogeneous emphysema subjects with severe hyperinflation, the EASE - study. & Local ammendment: Protocol revision to evaluate the ExhaleUltraNeedle in the EASE study.COPD10038716EmphysemaNL-OMON30701Broncus Technologies Inc.15
进行中（未招募）
1 期
Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host diseaseAcute graft versus host disease (GVHD)MedDRA version: 20.0Level: PTClassification code 10075160Term: Graft versus host disease in gastrointestinal tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2021-004588-29-ESVectivBio AG34
进行中（未招募）
不适用
Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous beta-blocker or calcium channel blockerEUCTR2006-001998-25-DETakeda Pharma GmbH
进行中（未招募）
不适用
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathyeuropathic pain from lumbosacral radiculopathyMedDRA version: 12.0Level: LLTClassification code 10037779Term: RadiculopathyEUCTR2009-012836-33-DEGlaxoSmithKline Research & Development Limited142